ST. LOUIS, Nov. 20, 2024 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), a leader in surgical robotics for minimally invasive procedures, has announced that Hospital da Luz in Lisbon, Portugal, has successfully treated its first patients using the Genesis Robotic Magnetic Navigation (RMN) System.
Prof. Pedro Adragão, a cardiac electrophysiologist at Hospital da Luz, expressed enthusiasm about the new technology, stating, “We are excited to be at the forefront of technology and patient care by introducing the new Genesis System at Hospital da Luz. Robotics allows us to provide effective individualized therapy with a strong focus on safety. We are pleased to offer this high-level care to all our patients, including those with the most complex arrhythmias. We also look forward to advancing this important technology for the benefit of patients and medical progress.”
Hospital da Luz Lisboa is affiliated with Luz Saude, the largest health group in Portugal. It is recognized as a global leader in diagnosing and treating complex heart conditions, having conducted over 4,000 robotic cardiac ablation procedures.
The Genesis System represents a significant advancement in Robotic Magnetic Navigation technology. This system enhances cardiac ablation procedures—minimally invasive treatments used to correct arrhythmias, which are abnormal heart rhythms that can lead to serious health risks if untreated.
David Fischel, Chairman and CEO of Stereotaxis, stated, “We are delighted to expand our long-term relationship with Prof.
Adragão and Hospital da Luz. We look forward to supporting their efforts to improve patient care, advance clinical science, and pioneer robotic innovation.”
Related topics:
- AHA 2024: Boston Scientific And Abbott Present Long-Term Data on Heart Occluders
- Extreme Heat Linked to Increased Risk of Atrial Arrhythmias in Patients with Implantable Devices
- Smartcardia’s ECG Patch Receives FDA Approval for Outpatient Cardiac Monitoring